info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Generic Pharmaceuticals Contract Manufacturing Market Research Report By Product Type (Pharmaceutical APIs, Formulations, Capsules, Tablets, Injectables), By Manufacturing Process (Chemical Synthesis, Biotechnology, Sterile Manufacturing, Solid Dose Manufacturing, Liquid Manufacturing), By Application (Generic Pharmaceuticals, Over-the-Counter Drugs, Biosimilars, Contract Manufacturing), By Business Model (Full-Service Contract Manufacturing, Semi-Integrated Contract Manufacturing, Capacity-Based Contract Manufacturing, Fee-for-Service Cont


ID: MRFR/HC/27866-HCR | 128 Pages | Author: Rahul Gotadki| October 2024

Generic Pharmaceuticals Contract Manufacturing Market Overview:


As per MRFR analysis, the Generic Pharmaceuticals Contract Manufacturing Market Size was estimated at 65.84 (USD Billion) in 2022. The Generic Pharmaceuticals Contract Manufacturing Market is expected to grow from 69.91 (USD Billion) in 2023 to 120.0 (USD Billion) by 2032. The Generic Pharmaceuticals Contract Manufacturing Market CAGR (growth rate) is expected to be around 6.18% during the forecast period (2024 - 2032).


Key Generic Pharmaceuticals Contract Manufacturing Market Trends Highlighted


The generic pharmaceutical contract manufacturing market is experiencing a surge in demand due to the increasing prevalence of chronic diseases and the expiration of patents for branded drugs.


Additionally, the rising cost of healthcare and government initiatives to promote access to affordable medications are driving the growth of this market. Key market drivers include the expansion of emerging markets, the adoption of biosimilars, and the increasing demand for complex generic products.


Opportunities to be explored or captured include the development of innovative manufacturing technologies, the expansion into new therapeutic areas, and the establishment of partnerships with pharmaceutical companies.


Recent trends in the market include the integration of digital technologies, the focus on sustainability, and the growing importance of quality and regulatory compliance.


 


Generic Pharmaceuticals Contract Manufacturing Market 1


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Generic Pharmaceuticals Contract Manufacturing Market Drivers


 


Increasing Demand for Generic Pharmaceuticals


The rising cost of healthcare has led to an increased demand for generic pharmaceuticals. Generic drugs are just as effective as brand-name drugs, but they are significantly cheaper. This has made them a more attractive option for patients and healthcare providers alike.


The growing demand for generic pharmaceuticals is expected to continue to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market. The Generic Pharmaceuticals Contract Manufacturing Market is expected to witness significant growth over the next decade.


 


The market is projected to grow from USD 69.91 billion in 2023 to USD 120.0 billion by 2032, at a CAGR of 6.18%. The increasing demand for generic pharmaceuticals is one of the key factors driving the growth of the market.


Generic pharmaceuticals are typically manufactured by contract manufacturing organizations (CMOs). CMOs provide a range of services to pharmaceutical companies, including drug development, manufacturing, and packaging. The use of CMOs allows pharmaceutical companies to focus on their core competencies and reduce their operating costs.


 


The growing number of CMOs is also expected to contribute to the growth of the Generic Pharmaceuticals Contract Manufacturing Market. In addition to the increasing demand for generic pharmaceuticals, the rising cost of drug development is also driving the growth of the Generic Pharmaceuticals Contract Manufacturing Market.


The cost of developing a new drug can exceed USD 1 billion. This has made it increasingly difficult for pharmaceutical companies to develop new drugs.


 


As a result, pharmaceutical companies are increasingly turning to CMOs to help them develop and manufacture their drugs. The Generic Pharmaceuticals Contract Manufacturing Market is a highly competitive market. The key players in the market include Lonza Catalent Patheon Thermo Fisher Scientific Samsung Biologics. These companies offer a range of services to pharmaceutical companies, including drug development, manufacturing, and packaging. The competitive landscape of the market is expected to remain fragmented over the next decade.


Technological Advancements


Technological advancements are also playing a key role in the growth of the Generic Pharmaceuticals Contract Manufacturing Market. The development of new technologies is making it possible to produce generic drugs more efficiently and cost-effectively.


For example, the use of continuous manufacturing is reducing the time and cost of drug production. The development of new drug delivery systems is also making it possible to deliver generic drugs in a more targeted and effective manner. The increasing adoption of new technologies is expected to continue to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market.


 


CMOs are investing in new technologies to improve their efficiency and productivity. This is expected to lead to lower costs and shorter lead times for the production of generic drugs. The development of new technologies is also expected to lead to the development of new generic drugs.


CMOs are working with pharmaceutical companies to develop new generic drugs that are more effective and affordable. This is expected to further drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market.


Government Regulations


Government regulations are also playing a role in the growth of the Generic Pharmaceuticals Contract Manufacturing Market. Governments are increasingly implementing policies to promote the use of generic drugs.


For example, the US government has implemented a number of policies to increase the availability and affordability of generic drugs. These policies have helped to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market. Governments are also implementing policies to regulate the manufacture of generic drugs.


 


These policies are designed to ensure that generic drugs are safe and effective. The implementation of these policies is expected to continue to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market.


 


Generic Pharmaceuticals Contract Manufacturing Market Segment Insights:


 


Generic Pharmaceuticals Contract Manufacturing Market Product Type Insights


 


The Generic Pharmaceuticals Contract Manufacturing Market is segmented by product type into Pharmaceutical APIs, Formulations, Capsules, Tablets, and Injectables. Among these, the Formulation segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period.


The growth of this segment can be attributed to the increasing demand for generic drugs and the rising popularity of outsourcing pharmaceutical manufacturing. The Pharmaceutical APIs segment is also expected to witness significant growth during the forecast period due to the increasing demand for active pharmaceutical ingredients (APIs) from generic drug manufacturers.


 


The growing adoption of biosimilars is also expected to contribute to the growth of this segment. The Capsules segment is another major segment in the Generic Pharmaceuticals Contract Manufacturing Market. The growth of this segment can be attributed to the increasing demand for oral solid dosage forms.


The rising popularity of modified-release capsules is also expected to contribute to the growth of this segment. The Tablets segment is also expected to witness significant growth during the forecast period. The growth of this segment can be attributed to the increasing demand for generic tablets.


 


The rising popularity of chewable and sublingual tablets is also expected to contribute to the growth of this segment. The Injectables segment is expected to witness moderate growth during the forecast period.


The growth of this segment can be attributed to the increasing demand for generic injectables. The rising popularity of self-injectable drugs is also expected to contribute to the growth of this segment. Overall, the Generic Pharmaceuticals Contract Manufacturing Market is expected to witness significant growth during the forecast period.


 


The growth of the market can be attributed to the increasing demand for generic drugs, the rising popularity of outsourcing pharmaceutical manufacturing, and the growing adoption of biosimilars.


 


Generic Pharmaceuticals Contract Manufacturing Market 2


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


 


Generic Pharmaceuticals Contract Manufacturing Market Manufacturing Process Insights


 


The Generic Pharmaceuticals Contract Manufacturing Market is segmented by Manufacturing Process into Chemical Synthesis, Biotechnology, Sterile Manufacturing, Solid Dose Manufacturing, and Liquid Manufacturing.


Among these segments, Chemical Synthesis held the largest market share of 38.4% in 2023. The Chemical Synthesis segment is expected to continue to dominate the market during the forecast period, owing to the increasing demand for generic drugs and the cost-effectiveness of chemical synthesis compared to other manufacturing processes.


 


The Biotechnology segment is expected to exhibit the highest CAGR of 7.2% during the forecast period due to the growing demand for biosimilars and the increasing adoption of biotechnology for the production of complex generic drugs.


 


Generic Pharmaceuticals Contract Manufacturing Market Application Insights


 


The application segment of the Generic Pharmaceuticals Contract Manufacturing Market is classified into Generic Pharmaceuticals, Over-the-Counter Drugs, Biosimilars, and Contract Manufacturing. Among these, Generic Pharmaceuticals holds the largest market share and is projected to continue its dominance throughout the forecast period.


The increasing demand for affordable healthcare solutions, coupled with the growing prevalence of chronic diseases, is driving the growth of this segment. Over-the-counter drugs and Biosimilars are also anticipated to witness significant growth in the coming years due to the rising awareness about self-medication and the increasing adoption of biologics.


 


Contract Manufacturing is expected to contribute substantially to the market growth as pharmaceutical companies outsource their manufacturing processes to reduce costs and focus on core competencies.


 


Generic Pharmaceuticals Contract Manufacturing Market Business Model Insights


 


The Generic Pharmaceuticals Contract Manufacturing Market is segmented based on the Business Model into Full-Service Contract Manufacturing, Semi-Integrated Contract Manufacturing, Capacity-Based Contract Manufacturing, and Fee-for-Service Contract Manufacturing.


Among these, the Full-Service Contract Manufacturing segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. This is attributed to the comprehensive services offered by full-service contract manufacturers, including product development, manufacturing, packaging, and distribution.


 


Additionally, the growing demand for outsourcing non-core activities by pharmaceutical companies is driving the growth of this segment. The Fee-for-Service Contract Manufacturing segment is expected to witness the highest growth rate during the forecast period due to its flexibility and cost-effectiveness.


 


Generic Pharmaceuticals Contract Manufacturing Market Regional Insights


 


The regional market segments exhibit diverse growth patterns in the Generic Pharmaceuticals Contract Manufacturing Market. North America held the largest revenue share in 2023 and is expected to maintain its dominance throughout the forecast period.


The growth in this region can be attributed to the presence of major pharmaceutical companies and contract manufacturers, as well as favorable government regulations. Europe is the second-largest market, driven by strong demand for generic pharmaceuticals in countries such as Germany, France, and the United Kingdom.


 


The APAC region is projected to witness significant growth over the next decade, fueled by increasing healthcare expenditure and rising demand for affordable generic drugs in emerging economies like India and China.


South America and MEA are expected to experience steady growth, driven by expanding healthcare infrastructure and government initiatives to improve access to affordable medicines. These insights can assist market players in tailoring their strategies to target specific regional markets and capitalize on growth opportunities.


Generic Pharmaceuticals Contract Manufacturing Market 3


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


 


Generic Pharmaceuticals Contract Manufacturing Market Key Players and Competitive Insights:


In the competitive Generic Pharmaceuticals Contract Manufacturing Market, leading players are constantly innovating and expanding their offerings to gain market share. Contract manufacturers such as Piramal Pharma Solutions, Jubilant HollisterStier, and Hetero Labs are investing heavily in research and development to create new and improved generic pharmaceuticals.


They are also expanding their geographical reach through acquisitions and partnerships to cater to the growing demand for generic drugs in emerging markets.


 


One of the leading players in the Generic Pharmaceuticals Contract Manufacturing Market is Piramal Pharma Solutions. The company has a strong track record of delivering high-quality generic drugs to its customers and is known for its expertise in complex generic formulations.


Piramal Pharma Solutions has a global presence with manufacturing facilities in North America, Europe, and Asia. The company's focus on innovation and customer service has helped it to become a trusted partner for many generic pharmaceutical companies.


 


A major competitor in the Generic Pharmaceuticals Contract Manufacturing Market is Hetero Labs. The company is one of the largest manufacturers of generic drugs in India and has a growing presence in international markets.


Hetero Labs is known for its low-cost manufacturing capabilities and its ability to produce high-quality generic drugs. The company has a strong pipeline of new generic products and is investing heavily in research and development to expand its product portfolio.


Key Companies in the Generic Pharmaceuticals Contract Manufacturing Market Include:



  • Ajinomoto Health Nutrition

  • Hetero Labs

  • Thermo Fisher Scientific

  • Catalent

  • Reddy's Laboratories

  • Fresenius Kabi

  • Stada Arzneimittel

  • Torrent Pharmaceuticals

  • Baxter

  • Teva Pharmaceutical Industries

  • Aurobindo Pharma

  • Zydus Cadila

  • Reckitt Benckiser

  • Lonza


Generic Pharmaceuticals Contract Manufacturing Market Developments


The growth of the market is attributed to the increasing demand for generic drugs, the rising prevalence of chronic diseases, and the growing adoption of outsourcing by pharmaceutical companies.


 


Recent news developments in the market include


- In February 2023, Lonza announced the expansion of its biologics manufacturing facility in Visp, Switzerland, to meet the growing demand for generic biologics.


- In March 2023, Catalent acquired Micron Technologies, a leading provider of clinical trial services, to enhance its drug development capabilities.


- In April 2023, Thermo Fisher Scientific launched a new bioproduction facility in Singapore to support the production of generic vaccines and antibody-based therapies.


Generic Pharmaceuticals Contract Manufacturing Market Segmentation Insights


 



  • Generic Pharmaceuticals Contract Manufacturing Market Product Type Outlook

  • Pharmaceutical APIs

  • Formulations

  • Capsules

  • Tablets

  • Injectables


 



  • Generic Pharmaceuticals Contract Manufacturing Market Manufacturing Process Outlook

  • Chemical Synthesis

  • Biotechnology

  • Sterile Manufacturing

  • Solid Dose Manufacturing

  • Liquid Manufacturing


 



  • Generic Pharmaceuticals Contract Manufacturing Market Application Outlook

  • Generic Pharmaceuticals

  • Over-the-Counter Drugs

  • Biosimilars

  • Contract Manufacturing


 



  • Generic Pharmaceuticals Contract Manufacturing Market Business Model Outlook

  • Full-Service Contract Manufacturing

  • Semi-Integrated Contract Manufacturing

  • Capacity-Based Contract Manufacturing

  • Fee-for-Service Contract Manufacturing


 



  • Generic Pharmaceuticals Contract Manufacturing Market Regional Outlook

  • North America

  • Europe

  • South America

  • Asia Pacific

  • Middle East and Africa

Report Attribute/Metric Details
Market Size 2022 65.84(USD Billion)
Market Size 2023 69.91(USD Billion)
Market Size 2032 120.0(USD Billion)
Compound Annual Growth Rate (CAGR) 6.18% (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
Market Forecast Units USD Billion
Key Companies Profiled Ajinomoto Health Nutrition, Hetero Labs, Thermo Fisher Scientific, Catalent, Dr. Reddy's Laboratories, Fresenius Kabi, Stada Arzneimittel, Torrent Pharmaceuticals, Baxter, Teva Pharmaceutical Industries, Aurobindo Pharma, Zydus Cadila, Reckitt Benckiser, Lonza
Segments Covered Product Type, Manufacturing Process, Application, Business Model, Regional
Key Market Opportunities Expanding the use of biologics Government initiatives for promoting generics Growing demand for cost-effective medications Technological advancements Strategic alliances and partnerships
Key Market Dynamics Rising drug patent expirations, increasing demand for cost-effective alternatives, growing prevalence of chronic diseases, government initiatives, and technological advancements
Countries Covered North America, Europe, APAC, South America, MEA


Frequently Asked Questions (FAQ) :

The Generic Pharmaceuticals Contract Manufacturing Market size was valued at USD 69.91 billion in 2023 and is projected to reach USD 120.0 billion by 2032, exhibiting a CAGR of 6.18% during the forecast period.

North America is expected to dominate the Generic Pharmaceuticals Contract Manufacturing Market, accounting for a significant share due to the presence of major pharmaceutical companies and favorable government policies.

Rising demand for affordable generic drugs, increasing outsourcing of manufacturing processes by pharmaceutical companies, and advancements in technology are the key growth drivers of the Generic Pharmaceuticals Contract Manufacturing Market.

Major players in the Generic Pharmaceuticals Contract Manufacturing Market include Lonza, Catalent, Thermo Fisher Scientific, Patheon, and Samsung Biologics.

Generic Pharmaceuticals Contract Manufacturing is used in the production of a wide range of generic drugs, including antibiotics, cardiovascular drugs, and oncology drugs.

The Generic Pharmaceuticals Contract Manufacturing Market faces challenges such as regulatory compliance, quality control, and competition from low-cost manufacturers.

The Generic Pharmaceuticals Contract Manufacturing Market is expected to grow at a CAGR of 6.18% from 2024 to 2032.

Increasing demand for affordable generic drugs, rising outsourcing of manufacturing processes, and technological advancements are expected to drive the growth of the Generic Pharmaceuticals Contract Manufacturing Market.

Key trends in the Generic Pharmaceuticals Contract Manufacturing Market include the adoption of continuous manufacturing technologies, the use of data analytics to optimize processes, and the growth of personalized medicine.

The COVID-19 pandemic has had a significant impact on the Generic Pharmaceuticals Contract Manufacturing Market, leading to increased demand for essential generic drugs and accelerated the adoption of digital technologies.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.